MDR-1339,1018946-38-7

MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务。

MDR-1339

CAS No. : 1018946-38-7

MCE 国际站：MDR-1339

产品活性：MDR-1339 (DWK-1339) 是一种可口服的，透过血脑屏障的 Aβ 聚集抑制剂，可用于阿尔兹海默症的研究。

研究领域：Neuronal Signaling

作用靶点：Amyloid-β

In Vitro: MDR-1339 is an Aβ-aggregation inhibitor, and shows no significant inhibition a panel of CYP isozymes, while it slightly inhibits CYP2C8 (IC₅₀, 31.4 μM). MDR-1339 (3.1-50 μM) dose-dependently blocks the formation of Aβ aggregates, and disaggregates Aβ fibrils. MDR-1339 (1.5-10 μM) also protects cells from this Aβ-induced toxicity.

In Vivo: MDR-1339 (0.1-10 mg/kg, p.o.) dose-dependently restores the passive avoidance responses in mice models of Alzheimer's disease (AD), with an ED₅₀ of 0.19 mg/kg. MDR-1339 (30 and 100 mg/kg, p.o. daily for 8 weeks) significantly improves spontaneous alternation, and reduces the Aβ_1-40 and Aβ_1-42 levels in APP/PS1 mice.

相关产品：Bioactive Compound Library Plus  |  Neuronal Signaling Compound Library  |  CNS-Penetrant Compound Library  |  Orally Active Compound Library  |  Anti-Alzheimer's Disease Compound Library  |  Neurodegenerative Disease-related Compound Library  |  Targeted Diversity Library  |  Membrane Protein-targeted Compound Library  |  DAPT  |  β-Amyloid (25-35)  |  Thioflavin T  |  β-Amyloid (1-42), human TFA  |  FPS-ZM1  |  Colivelin TFA  |  Rutin  |  Azeliragon  |  20(S)-Ginsenoside Rg3  |  Ginsenoside Rg1  |  β-Amyloid (1-42), (rat/mouse)  |  Tolcapone  |  Geniposide  |  Methoxy-X04  |  Emrusolmin  |  Semagacestat  |  Ginsenoside Re  |  Aducanumab  |  Notoginsenoside R1  |  Bavachinin  |  Licochalcone B  |  Hoechst 34580 tetrahydrochloride  |  β-Amyloid (1-40)  |  Direct Blue 1  |  Leucomethylene blue mesylate  |  Valiltramiprosate  |  Glimepiride  |  Hematoxylin  |  Chemerin-9 (149-157) (TFA)

热门产品线：重组蛋白  |  化合物库  |  天然产物  |  荧光染料  |  PROTAC  |  同位素标记物

Trending products：Recombinant Proteins  |  Bioactive Screening Libraries  |  Natural Products  |  Dye Reagents  |  PROTAC  |  Isotope-Labeled Compounds